UK-based Proteome Sciences announced last week that Alf Erik Anton Lindberg has been appointed to the company’s board of directors as a non-executive director, effective Oct. 1.
Lindberg was formerly executive vice-president of research and development and a board member of Aventis Pasteur. Aside from being a director at Proteome Scineces, Lindberg is also currently a director of Microscience Limited, Medivir, Gemvax and Vaxin.
Lindberg replaces WMM Schuller, who retired as a non-executive director on Sept. 30.
Vamsi Mootha is one of 23 new MacArthur fellows named by the MacArthur Foundation last week. Each fellow will receive $500,000 over the next five years. Mootha is an assistant professor of systems biology at Harvard Medical School. He was honored for “tapping into the wellspring of new data from molecular biology, genetics, and protein chemistry to identify the cause of, and possible treatment for, metabolic disease such as diabetes.”
Gavin MacBeath of the department of chemistry and chemical biology at Harvard University has received a grant from the W.M. Keck Foundation under the Distinguished Young Scholars in Medical Research Program. MacBeath, who has been developing protein microarrays as part of his research, plans to study protein interactions in cells. Each recipient’s institution receives an award of up to $1 million to support the scientist’s research activities for a period of up to five years.
Matritech, a Newton, Mass.-based company that develops protein-based diagnostic products for the early detection of cancer, announced that its board of directors has elected Gary Fagan to be the vice president of research and development.
Fagan had served as the senior director of product development since November 2003. Prior to joining Matritech, Fagan was the vice president of research and development at Ischemia Technologies, where he was responsible for the development and commercialization of an automated chemistry assay for the rapid diagnosis of cardiac ischemia.
Prior to joining Ischemia, Fagan spent six years at Dade Behring Diagnositics where he was became the company’s senior research manager.